{"title":"医疗保健专业人员必须与患者和家属沟通。他们必须在临终药物治疗中做出明智、现实和适当的决定","authors":"Amanda J Lee","doi":"10.1136/ebnurs-2019-103179","DOIUrl":null,"url":null,"abstract":"Commentary on: Morin L, Wastesson JW, Laroche ML, et al . How many older adults receive drugs of questionable clinical benefit near the end of life? A cohort study. Palliat Med 2019;33:1080–90. doi: 10.1177/0269216319854013.\n\n\n\nUse of a variety of drugs (polypharmacy) is required to manage complex disease processes. At the end of life, the focus of ‘treatment’ changes from extending survival to symptom management—therefore, aims of treatments change, requiring different pharmaceutical …","PeriodicalId":12178,"journal":{"name":"Evidence Based Journals","volume":"139 1","pages":"12 - 12"},"PeriodicalIF":0.0000,"publicationDate":"2019-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Healthcare professionals must communicate with patients and relatives. They must enable informed, realistic and appropriate decisions in end-of-life pharmacotherapy\",\"authors\":\"Amanda J Lee\",\"doi\":\"10.1136/ebnurs-2019-103179\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Commentary on: Morin L, Wastesson JW, Laroche ML, et al . How many older adults receive drugs of questionable clinical benefit near the end of life? A cohort study. Palliat Med 2019;33:1080–90. doi: 10.1177/0269216319854013.\\n\\n\\n\\nUse of a variety of drugs (polypharmacy) is required to manage complex disease processes. At the end of life, the focus of ‘treatment’ changes from extending survival to symptom management—therefore, aims of treatments change, requiring different pharmaceutical …\",\"PeriodicalId\":12178,\"journal\":{\"name\":\"Evidence Based Journals\",\"volume\":\"139 1\",\"pages\":\"12 - 12\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-11-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Evidence Based Journals\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ebnurs-2019-103179\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Evidence Based Journals","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ebnurs-2019-103179","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Healthcare professionals must communicate with patients and relatives. They must enable informed, realistic and appropriate decisions in end-of-life pharmacotherapy
Commentary on: Morin L, Wastesson JW, Laroche ML, et al . How many older adults receive drugs of questionable clinical benefit near the end of life? A cohort study. Palliat Med 2019;33:1080–90. doi: 10.1177/0269216319854013.
Use of a variety of drugs (polypharmacy) is required to manage complex disease processes. At the end of life, the focus of ‘treatment’ changes from extending survival to symptom management—therefore, aims of treatments change, requiring different pharmaceutical …